Uno studio di TP-3654 orale in pazienti con mielofibrosi
Uno studio di fase 1/2, in aperto, aumento della dose, sicurezza, farmacocinetica e farmacodinamica del TP-3654 orale in pazienti con mielofibrosi primaria o secondaria a rischio intermedio o alto
This study is a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics and pharmacodynamics of nuvisertib (TP-3654) in patients with intermediate or high-risk primary or secondary MF.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
Arm 1 will enroll patients who have been previously treated and failed on a JAK inhibitor or ineligible to receive treatment with a JAK inhibitor.
Arm 2 will enroll patients who are on a stable dose of ruxolitinib, but who have either lost response or had a suboptimal or plateau in response.
Arm 3 will enroll patients who have been previously treated with a JAK inhibitor (except momelotinib)
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Fase 2
- Fase 1
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: Reyna Bishop
- Numero di telefono: 617-674-6800
- Email: reyna.bishop@us.sumitomo-pharma.com
Backup dei contatti dello studio
- Nome: Jordan Simpson
- Email: jordan.simpson@us.sumitomo-pharma.com
Luoghi di studio
-
-
-
Adelaide, Australia
- Reclutamento
- Icon Cancer Centre (Ashford Cancer Centre Research)
-
Contatto:
- Stanley Cheung, MD
- Email: Stanley.Cheung@icon.team
-
-
South Australia
-
Adelaide, South Australia, Australia
- Reclutamento
- Royal Adelaide Hospital
-
Contatto:
- Christine Hoare
- Email: christine.hoare@sa.gov.au
-
-
Victoria
-
Box Hill, Victoria, Australia
- Reclutamento
- Eastern Health Box Hill Hospital
-
Contatto:
- SMPA Investigative Site
-
Clayton, Victoria, Australia
- Reclutamento
- Monash University
-
Contatto:
- SMPA Investigative Site
-
Fitzroy, Victoria, Australia
- Reclutamento
- St Vincent's Hospital Melbourne
-
Contatto:
- SMPA Investigative Site
-
Melbourne, Victoria, Australia
- Reclutamento
- Peter McCallum Center
-
Contatto:
- SMPA Investigative Site
-
Richmond, Victoria, Australia
- Reclutamento
- Epworth Healthcare
-
Contatto:
- SMPA Investigative Site
-
-
-
-
-
Antwerp, Belgio, 2020
- Reclutamento
- ZNA Cadix
-
Contatto:
- SMPA Investigative Site
-
Antwerp, Belgio, 2030
- Reclutamento
- ZNA Middelheim
-
Contatto:
- SMPA Investigative Site
-
Ghent, Belgio, 9000
- Reclutamento
- Universitair Ziekenhuis Gent
-
Contatto:
- SMPA Investigative Site
-
Liège, Belgio, 4000
- Reclutamento
- CHU de Liege
-
Contatto:
- SMPA Investigative Site
-
-
Vlaams-Brabant
-
Leuven, Vlaams-Brabant, Belgio, 3000
- Reclutamento
- University Hospitals Leuven
-
Contatto:
- SMPA Investigative Site
-
-
-
-
Alberta
-
Calgary, Alberta, Canada, T2N 1N4
- Reclutamento
- University of Calgary
-
Contatto:
- Sonia Cerquozzi
- Email: sonia.cerquozzi@albertahealthservices.ca
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V6T 1Z3
- Reclutamento
- University of British Columbia
-
Contatto:
- SMPA Investigative Site
-
Vancouver, British Columbia, Canada, V6T 1Z3
- Reclutamento
- St. Paul's Hospital Hematology/Oncology Research
-
Contatto:
- Kelsi Sorensen
- Numero di telefono: 604-682-2344
- Email: ksorensen1@providencehealth.bc
-
-
Ontario
-
Hamilton, Ontario, Canada, L8V 5C2
- Reclutamento
- Juravinski Cancer Center
-
Contatto:
- SMPA Investigative Site
-
Toronto, Ontario, Canada, M5G 2M9
- Reclutamento
- Princess Margaret Cancer Center
-
Contatto:
- Vikas Gupta
- Email: vikas.gupta@uhn.ca
-
-
Quebec
-
Montreal, Quebec, Canada, H3T 1E2
- Reclutamento
- Jewish General Hospital
-
Contatto:
- SMPA Investigative Site
-
-
-
-
-
Amiens, Francia, 80054
- Reclutamento
- Centre Hospitalier Universitaire D'Amiens
-
Contatto:
- SMPA Investigative Site
-
Angers, Francia, 9000
- Reclutamento
- CHU Angers
-
Contatto:
- SMPA Investigative Site
-
Lyon, Francia, 69495
- Reclutamento
- Centre Hospitalier Lyon Sud
-
Contatto:
- SMPA Investigative Site
-
Nice, Francia, 06200
- Reclutamento
- Hospitalier Universitaire (CHU) de Nice - Hopital de l'Archet
-
Contatto:
- SMPA Investigative Site
-
Nîmes, Francia, 30029
- Reclutamento
- Institut de cancerologie du Gard
-
Contatto:
- SMPA Investigative Site
-
Nîmes, Francia
- Reclutamento
- Institut de cancerologie du Gard
-
Contatto:
- SMPA Investigative Site
-
Paris, Francia, 75010
- Reclutamento
- Hospital Saint Louis
-
Contatto:
- SMPA Investigative Site
-
Poitiers, Francia, 86021
- Reclutamento
- University Hospital of Poitiers
-
Contatto:
- SMPA Investigative Site
-
Villejuif, Francia, 94805
- Reclutamento
- Institut Gustave Roussy
-
Contatto:
- SMPA Investigative Site
-
-
-
-
-
Halle, Germania
- Reclutamento
- Universitätsmedizin Halle
-
Contatto:
- SMPA Investigative Site
-
Lübeck, Germania
- Reclutamento
- Universitätsklinikum Schleswig-Holstein
-
Contatto:
- SMPA Investigative Site
-
-
-
-
-
Aichi, Giappone
- Reclutamento
- Aichi Medical University Hospital
-
Contatto:
- Akiyoshi Takami
- Numero di telefono: 0561-62-3311
- Email: takami.akiyoshi.490@mail.aichi-med-u.ac.jp
-
Aomori, Giappone
- Reclutamento
- Aomori Prefectural Central Hospital
-
Contatto:
- Tomoaki Akagi, MD
- Numero di telefono: 017-726-8111
- Email: tomakagi@med.pref.aomori.jp
-
Chiba, Giappone
- Reclutamento
- National Cancer Center Hospital East
-
Contatto:
- Junichiro Yuda, MD
- Numero di telefono: 04-7133-1111
- Email: jyuda@east.ncc.go.jp
-
Fukuoka, Giappone
- Reclutamento
- Kyushu University Hospital
-
Contatto:
- Takuji Yamauchi, MD
- Numero di telefono: 092-641-1151
- Email: yamauchi.takuji.355@m.kyushu-u.ac.jp
-
Hokkaido, Giappone
- Reclutamento
- Hokkaido University Hospital
-
Contatto:
- Takanori Teshima, MD
- Numero di telefono: 011-716-1161
- Email: teshima@med.hokudai.ac.jp
-
Kamakura, Giappone, 247-8533
- Reclutamento
- Shonan Kamakura General Hospital
-
Contatto:
- Tomiteru Togano, MD
- Numero di telefono: 0467-46-1717
- Email: t_togano@shonankamakura.or.jp
-
Miyazaki, Giappone
- Reclutamento
- University of Miyazaki Hospital
-
Contatto:
- Kazuya Shimoda, MD
- Numero di telefono: 0985-85-1510
- Email: kshimoda@med.miyazaki-u.ac.jp
-
Okayama, Giappone
- Reclutamento
- Okayama University Hospital
-
Contatto:
- Noboru Asada, MD
- Numero di telefono: 086-223-7151
- Email: nasada@okayama-u.ac.jp
-
Osaka, Giappone
- Reclutamento
- The University of Osaka Hospital
-
Contatto:
- Michiko Ichii, MD
- Numero di telefono: 06-6879-5111
-
Saitama, Giappone
- Completato
- Saitama Medical Center
-
Sendai, Giappone
- Reclutamento
- Tohoku University Hospital
-
Contatto:
- Noriko Fukuhara, MD
- Numero di telefono: 022-717-7000
-
Shizuoka, Giappone
- Completato
- Shizuoka Cancer Center
-
Tokyo, Giappone, 160-0023
- Reclutamento
- Tokyo Medical University Hospital
-
Contatto:
- Daigo Akahane, MD
- Numero di telefono: 03-3342-6111
- Email: dakahane@tokyo-med.ac.jp
-
Tokyo, Giappone
- Reclutamento
- Juntendo University Hospital
-
Contatto:
- Shuichi Shirane, MD
- Numero di telefono: 03-3813-3111
- Email: sshirane@juntendo.ac.jp
-
Tokyo, Giappone, 179-0072
- Reclutamento
- Nerima Hikarigaoka Hospital
-
Contatto:
- Akihiko Gotoh, MD
- Numero di telefono: 03-3979-3611
- Email: akgotou@juntendo.ac.jp
-
Tsu, Giappone
- Reclutamento
- Mie University Hospital
-
Contatto:
- Yuka Sugimoto, MD
- Numero di telefono: 059-232-1111
- Email: yuka2@clin.medic.mie-u.ac.jp
-
-
-
-
-
Alessandria, Italia, 15121
- Reclutamento
- Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo
-
Contatto:
- SMPA Investigative Site
-
Aviano, Italia, 33081
- Reclutamento
- Istituto Nazionale Tumori, IRCCS Centro di Riferimento Oncologico di Aviano
-
Bologna, Italia, 40138
- Reclutamento
- IRCCS Azienda Ospedaliero -Universitaria Di Bologna - Dipartimento Malattie Oncologiche ed Ematologiche - UO Ematologia
-
Contatto:
- SMPA Investigative Site
-
Brescia, Italia
- Reclutamento
- ASST - Spedali Civili di Brescia
-
Contatto:
- SMPA Investigative Site
-
Meldola, Italia, 47014
- Reclutamento
- IRCCS istituto Romagnolo per lo studio dei tumori "Dino Amadori"
-
Contatto:
- SMPA Investigative Site
-
Milan, Italia, 20122
- Reclutamento
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
-
Contatto:
- SMPA Investigative Site
-
Torino, Italia, 10126
- Reclutamento
- Azienda Ospedaliera Universitaria Citta' Della Salute E della Scienza di Torino
-
Contatto:
- SMPA Investigative Site
-
-
-
-
-
Lincoln, Regno Unito
- Reclutamento
- Lincoln County Hospital
-
Contatto:
- SMPA Investigative Site
-
Lincoln, Regno Unito
- Reclutamento
- United Lincolnshire Hospitals NHS Trust - Pilgrim Hospital
-
Contatto:
- SMPA Investigative Site
-
London, Regno Unito
- Reclutamento
- University College London Hospital's NHS foundation Trust
-
Contatto:
- SMPA Investigative Site
-
Oxford, Regno Unito
- Reclutamento
- Oxford University Hospitals NHS Foundation
-
Contatto:
- SMPA Investigative Site
-
-
-
-
-
Barcelona, Spagna
- Reclutamento
- Hospital Universitario y Politecnico La Fe
-
Contatto:
- SMPA Investigative Site
-
Barcelona, Spagna
- Reclutamento
- Institut Catala d'Oncologia
-
Contatto:
- SMPA Investigative Site
-
Salamanca, Spagna
- Reclutamento
- Hospital Universitario de Salamanca
-
Contatto:
- SMPA Investigative Site
-
-
-
-
Alabama
-
Birmingham, Alabama, Stati Uniti, 35294
- Reclutamento
- University of Alabama
-
Contatto:
- Tiffany Hill
- Numero di telefono: 205-934-9591
-
-
Arizona
-
Tucson, Arizona, Stati Uniti, 85724
- Reclutamento
- The University of Arizona Cancer Center
-
Contatto:
- Audrey Johnson
- Numero di telefono: 520-694-9084
- Email: audieejayy@arizona.edu
-
-
California
-
Duarte, California, Stati Uniti, 91010
- Reclutamento
- City of Hope
-
Contatto:
- Michelle Velasquez
- Numero di telefono: 626-218-3524
- Email: mvelaszuez@coh.org
-
Los Angeles, California, Stati Uniti, 90033
- Reclutamento
- University of Southern California
-
Contatto:
- Shirley Sian
- Numero di telefono: 323-865-0456
- Email: sian_s@med.usc.edu
-
Newport Beach, California, Stati Uniti, 92663
- Reclutamento
- Hoag Family Cancer Institute
-
Contatto:
- Patrice Jones
- Numero di telefono: 949-764-5501
- Email: patrice.jones@hoag.org
-
-
Colorado
-
Denver, Colorado, Stati Uniti, 80218
- Reclutamento
- Blood Cancer Center
-
Contatto:
- Brooke Rhodes
- Email: Brookerhodes@sarahcannon.com
-
-
Connecticut
-
New Haven, Connecticut, Stati Uniti, 06510
- Reclutamento
- Yale School of Medicine
-
Contatto:
- Farah Fasihuddin
- Numero di telefono: 203-494-4610
- Email: farah.fasihuddin@yale.edu
-
-
Florida
-
Gainesville, Florida, Stati Uniti, 32608
- Completato
- University of Florida Health Shands Cancer Hospital
-
Miami, Florida, Stati Uniti, 33136
- Reclutamento
- University of Miami
-
Contatto:
- Alessia Zoso
- Numero di telefono: 305-243-0327
- Email: azoso@miami.edu
-
Miami, Florida, Stati Uniti, 33176
- Reclutamento
- Baptist Health - Miami Cancer Institute
-
Contatto:
- Firas El Chaer, MD
- Numero di telefono: 786-596-2000
- Email: firas.elchaer@baptisthealth.net
-
-
Georgia
-
Atlanta, Georgia, Stati Uniti, 30322
- Reclutamento
- Emory University
-
Contatto:
- Suzanne Scott
- Numero di telefono: 404-778-4334
- Email: suzanne.e.scott@emory.edu
-
-
Illinois
-
Chicago, Illinois, Stati Uniti, 60637
- Reclutamento
- University of Chicago
-
Contatto:
- Howie Weiner
- Email: HWeiner@bsd.uchicago.edu
-
-
Maryland
-
Baltimore, Maryland, Stati Uniti, 21201
- Reclutamento
- University of Maryland
-
Contatto:
- Maria Baer, MD
- Numero di telefono: 410-328-8708
- Email: mbaer@umm.edu
-
-
Massachusetts
-
Boston, Massachusetts, Stati Uniti, 02114
- Reclutamento
- Massachusetts General Hospital
-
Contatto:
- Gabriela Hobbs, MD
- Email: ghobbs@mgb.org
-
-
Michigan
-
Ann Arbor, Michigan, Stati Uniti, 48109
- Reclutamento
- University of Michigan
-
Contatto:
- Kelsey Bolin
- Numero di telefono: 734-936-2193
- Email: kntillma@med.umich.edu
-
-
Minnesota
-
Minneapolis, Minnesota, Stati Uniti, 55455
- Reclutamento
- University of Minnesota
-
Contatto:
- Naveen Premnath, MD
- Email: premn007@umn.edu
-
-
Missouri
-
St Louis, Missouri, Stati Uniti, 63110
- Reclutamento
- Washington University of Medicine
-
Contatto:
- Nicole Gaudin
- Numero di telefono: 314-747-7960
- Email: nrgaudin@wustl.edu
-
-
New Jersey
-
Hackensack, New Jersey, Stati Uniti, 07601
- Reclutamento
- John Theurer Cancer Center at Hackensack University Medical Center
-
Contatto:
- Parita Patel
- Numero di telefono: 551-996-5900
- Email: parita.patel@hmhn.org
-
-
New York
-
Buffalo, New York, Stati Uniti, 14263
- Completato
- Roswell Park Comprehensive Cancer Center
-
New York, New York, Stati Uniti, 10065
- Reclutamento
- Memorial Sloan Kettering Cancer Center
-
Contatto:
- Tamanna Haque, MD
- Email: haquet1@mskcc.org
-
New York, New York, Stati Uniti, 10029
- Reclutamento
- Icahn School of Medicine at Mount Sinai
-
Contatto:
- Gabriela Bello
- Email: gabriela.bello@mssm.edu
-
New York, New York, Stati Uniti, 10065
- Reclutamento
- Weill Cornell Medical Center
-
Contatto:
- Penina Steward
- Numero di telefono: 212-746-1858
- Email: pes4006@med.cornell.edu
-
The Bronx, New York, Stati Uniti, 10461
- Reclutamento
- Montefiore Cancer Center
-
Contatto:
- Olivia Orellano
- Email: oorellano@montefiore.org
-
-
North Carolina
-
Durham, North Carolina, Stati Uniti, 27710
- Reclutamento
- Duke Cancer Institute
-
Contatto:
- Ben Dosan
- Email: benjamin.dosan@duke.edu
-
-
Ohio
-
Columbus, Ohio, Stati Uniti, 43210
- Reclutamento
- Ohio State University
-
Contatto:
- Molly Brandenburg
- Numero di telefono: 614-366-7951
- Email: Molly.Brandenburg@osumc.edu
-
-
South Carolina
-
Charleston, South Carolina, Stati Uniti, 29425
- Reclutamento
- Medical University of South Carolina
-
Contatto:
- Jared Hortman
- Email: hortman@musc.edu
-
-
Tennessee
-
Nashville, Tennessee, Stati Uniti, 37232
- Reclutamento
- Vanderbilt University
-
Contatto:
- SMPA Investigative Site
-
Nashville, Tennessee, Stati Uniti, 37203
- Reclutamento
- Tri-Star Centennial Medical Center
-
Contatto:
- Brooke Rhodes
- Email: brooke.rhodes@sarahcannon.com
-
-
Texas
-
Houston, Texas, Stati Uniti, 77054
- Reclutamento
- MD Anderson Cancer Center
-
Contatto:
- Kurt Schroeder
- Numero di telefono: 713-745-2232
- Email: kdschroe@mdanderson.org
-
-
Utah
-
Salt Lake City, Utah, Stati Uniti, 84112
- Reclutamento
- Huntsman Cancer Institute
-
Contatto:
- Nicole Fisher
- Numero di telefono: 801-587-7000
- Email: nicole.fisher@hci.utah.edu
-
-
Virginia
-
Charlottesville, Virginia, Stati Uniti, 22903
- Reclutamento
- University of Virginia Cancer Center
-
Contatto:
- Avani Hopkins
- Numero di telefono: 434-243-8108
- Email: AJH7JQE@uvahealth.org
-
-
Washington
-
Seattle, Washington, Stati Uniti, 98109
- Reclutamento
- University of Washington - Fred Hutchinson Cancer Center
-
Contatto:
- Anna Halpern
- Email: halpern2@uw.edu
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Patients must meet all of the following inclusion criteria to be eligible:
Nuvisertib (TP-3654) Monotherapy Arm:
- Confirmed pathological diagnosis of primary myelofibrosis (PMF) or post-PV-MF/post-ET- MF and intermediate or high-risk primary or secondary MF
- Previously treated with JAK inhibitor(s) and is intolerant, resistant, refractory or has lost response to the JAK inhibitor(s) or is ineligible to be treated with JAK inhibitor
- Fulfill the following clinical laboratory parameters:
- Platelet count ≥ 25 x 10^9 /L, without assistance of growth factors or platelet transfusions
- ANC ≥ 1 x 10^9/L without assistance of granulocyte growth factors
- Peripheral blood blast count < 5%
- ECOG performance status ≤ 1
- Life expectancy ≥ 6 months
- Adequate renal function
- Adequate hepatic function
- Adequate coagulation function
- Splenomegaly (spleen volume of ≥ 450 cm3 by MRI or CT scan) within 2 weeks prior to Cycle 1 Day 1.
- Dose escalation: At least 2 symptoms measurable (score ≥ 1) using the MF-SAF
- Dose expansion: At least 2 symptoms measurable with each score of ≥ 3 or a total average score of ≥ 10 per MFSAF
Nuvisertib (TP-3654) + Ruxolitinib Arm:
- Confirmed pathological diagnosis of PMF or post-PV-MF/post ET- MF and intermediate or high-risk primary or secondary MF
- On ruxolitinib treatment for ≥ 6 months, and on a stable dose of ruxolitinib (5 to 25 mg BID) for ≥ 8 weeks prior to the first dose of nuvisertib, but has either lost response or had a suboptimal or plateau in response
- Fulfills the following clinical laboratory parameters:
- Platelet count ≥ 50 × 10^9/L (without assistance of growth factors or platelet transfusions)
- ANC ≥ 1 × 109/L without assistance of granulocyte growth factors
- Peripheral blood blast count < 5% at screening
- Adequate renal function
- Adequate hepatic function
- Adequate coagulation function
- Splenomegaly (spleen volume of ≥ 450 cm3 by MRI/CT scan) within 2 weeks prior to Cycle 1 Day 1
- At least 2 symptoms measurable with each score ≥ 3 or a total average score of ≥ 10 per MFSAF v4.0
- ECOG performance status ≤ 1
- Life expectancy ≥ 6 months
Nuvisertib (TP-3654) + Momelotinib Arm
- Confirmed pathological diagnosis of PMF or post-PV-MF/post ET-MF and intermediate or high-risk primary or secondary MF
- Previously treated with an approved JAK inhibitor (except momelotinib) for PMF or Post-PV/ET MF for ≥ 12 weeks, or ≥ 4 weeks if JAK inhibitor therapy was complicated by a transfusion requirement of ≥ 4 units of red blood cells in 8 weeks, or Grade 3/4 AEs of thrombocytopenia, anemia, or hematoma
- Fulfills the following clinical laboratory parameters:
- Anemic, defined as Hb <10 g/dL or requiring RBC transfusion at baseline
- Platelet count ≥ 50 × 109/L (without assistance of growth factors or platelet transfusions)
- ANC ≥ 1 × 109/L without assistance of granulocyte growth factors
- Peripheral blood blast count < 5% at screening
- Adequate renal function
- Adequate hepatic function
- Adequate coagulation function
- Splenomegaly (spleen volume of ≥ 450 cm3 by MRI/CT scan) within 2 weeks prior to Cycle 1 Day 1
- At least 2 symptoms measurable with each score of ≥ 3 or a total average score of ≥ 10 per MFSAF v4.0
- ECOG performance status ≤ 1
- Life expectancy ≥ 6 months
Patients meeting any one of these exclusion criteria will be prohibited from participating in this study:
Nuvisertib (TP-3654) Monotherapy Arm:
- Received previous systemic antineoplastic therapy or any experimental therapy within 2 weeks or 5 half-lives, whichever is longer, prior to Cycle 1 Day 1. Hydroxyurea or anagrelide are allowed up to 24 hours prior to Cycle 1 Day 1).
- Major surgery within 4 weeks prior to Cycle 1 Day 1 and/or not recovered adequately from from surgery prior to first dose.
- Splenic irradiation within 6 months prior to Screening or prior splenectomy.
- Prior allogeneic stem cell transplant within the last 6 months.
- Eligible for allogeneic bone marrow or stem cell transplantation.
- Unresolved Grade ≥ 2 non-hematological toxicity related to prior treatment
- History of symptomatic congestive heart failure, or myocardial infarction, or uncontrolled arrhythmia within 6 months prior to Cycle 1 Day 1; left ventricular ejection fraction (LVEF) < 45% by echocardiogram within 4 weeks prior to Cycle 1 Day 1.
- Corrected QT interval > 480msec.
- Prior or concurrent malignancy that could interfere with the investigational regime.
- Known history of chronic liver disease, e.g. portal hypertension or any of its complications, cirrhosis, Child-Pugh C, auto-immune hepatitis, alpha-1 anti-trypsin deficiency, Wilson's disease, etc.
- Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic antimicrobial within 1 week prior to Cycle 1 Day 1.
- Chronic active or acute viral hepatitis A, B, or C infection (testing for hepatitis B and C are required)
- Exhibited allergic reactions or sensitivity to nuvisertib, or similar compound.
- Medical condition or GI tract surgery that could impair absorption or result in short bowel syndrome with diarrhea.
- Systemic steroid therapy (>10 mg daily prednisone or equivalent) within 1 week prior to the first dose of study treatment (note: topical, inhaled, nasal, and ophthalmic steroids are not prohibited).
- Known clinically significant anemia due to iron, vitamin B12, or folate deficiencies, or autoimmune or hereditary hemolytic anemia, or thalassemia, or severe GI bleeding.
- Pregnant or breastfeeding
- Currently receiving any other investigational agent.
Nuvisertib (TP-3654) + Ruxolitinib Arm:
- Received previous systemic antineoplastic therapy (other than ruxolitinib) or any other experimental therapy within 2 weeks or 5 half-lives, whichever is longer, prior to Cycle 1 Day 1 (Note: Prior treatment with nuvisertib is not allowed. Hydroxyurea or anagrelide are allowed up to 24 hours prior to Cycle 1 Day 1).
- Received systemic steroid therapy (>10 mg daily prednisone or equivalent) within 1 week prior to Cycle 1 Day 1 (Note: Topical, inhaled, nasal, and ophthalmic steroids are not prohibited)
- Known allergic reactions or sensitivity to nuvisertib, or similar compound.
- Splenic irradiation within 6 months prior to Screening or prior splenectomy
- Prior allogeneic stem cell transplant within the last 6 months (Note: Patients who have relapsed after 6 months post-transplant and do not have active GVHD are eligible).
- Eligible for allogeneic bone marrow or stem cell transplantation (Note: Patients who are not willing to undergo transplantation or for whom a suitable donor is not available are considered as transplant ineligible.)
- Major surgery within 4 weeks prior to Cycle 1 Day 1 and/or have not recovered adequately prior to first dose.
- Active, uncontrolled bacterial, viral, or fungal infections, requiring parenteral antimicrobial within 1 week prior to Cycle 1 Day 1
- Chronic active or acute viral hepatitis A, B, or C infection (testing for hepatitis B and C are required)
- Known history of chronic liver disease (eg, portal hypertension or any of its complications, cirrhosis, Child-Pugh C, auto-immune hepatitis, alpha-1 anti-trypsin deficiency, Wilson's disease, etc) (Note: Abnormal liver morphology at baseline imaging may require additional testing, as needed).
- Unresolved Grade ≥ 2 non-hematological adverse events related to prior treatment (stable Grade 2 conditions may be permitted in consultation with the Sponsor)
- History of myocardial infarction or symptomatic congestive heart failure or uncontrolled arrhythmia within 6 months prior to Cycle 1 Day 1; LVEF <45% by echocardiogram within 4 weeks prior to Cycle 1 Day 1
- Corrected QTcF of > 480 msec
- Prior or concurrent malignancy that could interfere with the safety or efficacy assessment of the study intervention
- History of a medical condition or GI tract surgery that could impair absorption or could result in short bowel syndrome with diarrhea
- Known clinically significant anemia due to iron, vitamin B12, or folate deficiencies, or autoimmune or hereditary hemolytic anemia, or thalassemia, or severe GI bleeding
- Pregnant or breastfeeding
Nuvisertib (TP-3654) + Momelotinib Arm:
- Received previous systemic antineoplastic therapy or any experimental therapy within 2 weeks or 5 half-lives, whichever is longer, prior to Cycle 1 Day 1 (Notes: Prior treatment with momelotinib or nuvisertib is not allowed; in patients with ongoing JAK inhibitor therapy, ie, ruxolitinib, at screening, JAK inhibitor therapy must be tapered over a period of at least 1 week. Patients on a low dose of ruxolitinib (eg, 5 mg QD) may have a reduced taper period or no taper; hydroxyurea or anagrelide are allowed up to 24 hours prior to Cycle 1 Day 1).
- Received systemic steroid therapy (>10 mg daily prednisone or equivalent) within 1 week prior to Cycle 1 Day 1 (Note: Topical, inhaled, nasal, and ophthalmic steroids are not prohibited).
- Known allergic reactions or sensitivity to nuvisertib, momelotinib, or any structurally similar drug, or to any component of the formulations of either study intervention
- Splenic irradiation within 6 months prior to screening or prior splenectomy
- Prior allogenic stem cell transplant within the last 6 months (Note: Patients who have relapsed after 6 months post-transplant and do not have active GVHD are eligible).
- Eligible for allogeneic bone marrow or stem cell transplantation (Note: Patients who are not willing to undergo transplantation or for whom a suitable donor is not available are considered as transplant ineligible).
- Major surgery within 4 weeks prior to Cycle 1 Day 1 and/or have not recovered adequately from surgery prior to first dose.
- Active, uncontrolled bacterial, viral, or fungal infections, requiring parenteral antimicrobial within 1 week prior to Cycle 1 Day 1
- Chronic active or acute viral hepatitis A, B, or C infection (testing for hepatitis B and C are required)
- Known history of chronic liver disease (eg, portal hypertension or any of its complications, cirrhosis, Child-Pugh C, auto-immune hepatitis, alpha-1 anti-trypsin deficiency, Wilson's disease, etc) (Note: Abnormal liver morphology at baseline imaging may require additional testing, as needed)
- Unresolved Grade ≥ 2 non-hematological adverse events related to prior treatment (stable Grade 2 conditions may be permitted in consultation with the Sponsor)
- Presence of Grade ≥ 2 peripheral neuropathy
- History of myocardial infarction or symptomatic congestive heart failure or uncontrolled arrhythmia within 6 months prior to Cycle 1 Day 1; LVEF < 45% by echocardiogram within 4 weeks prior to Cycle 1 Day 1
- Corrected QTcF of > 480 msec
- Prior or concurrent malignancy that could interfere with the safety or efficacy assessment of the study intervention
- History of a medical condition or GI tract surgery that could impair absorption or could result in short bowel syndrome with diarrhea
- Known clinically significant anemia due to iron, vitamin B12, or folate deficiencies, or autoimmune or hereditary hemolytic anemia, or thalassemia, or severe GI bleeding
- Pregnant or breastfeeding
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Non randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Braccio 1: nuvisertib (TP-3654)
|
Oral PIM Inhibitor
Altri nomi:
|
|
Sperimentale: Braccio 2: nuvisertib (TP-3654) aggiunto a ruxolitinib
|
Oral PIM Inhibitor
Altri nomi:
Oral JAK inhibitor
Altri nomi:
|
|
Sperimentale: Braccio 3: nuvisertib (TP-3654) in combinazione con momelotinib
|
Oral PIM Inhibitor
Altri nomi:
Oral JAK inhibitor
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Determine the incidence of dose-limiting toxicities (DLTs)
Lasso di tempo: 28 days
|
Number of participants with DLTs |
28 days
|
|
Determine the incidence of treatment emergent adverse events
Lasso di tempo: From start of treatment to end of study
|
Number of participants with Treatment Emergent Adverse Events and Serious Adverse Events |
From start of treatment to end of study
|
|
Assess patients for any evidence of preliminary activity by determining the number of patients with ≥ 35% spleen volume reduction (SVR35)
Lasso di tempo: From start of treatment to end of study
|
Number of participants with ≥ 35% spleen volume reduction (SVR35) |
From start of treatment to end of study
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Number of participants achieving objective response by IWG-MRT response criteria
Lasso di tempo: From start of treatment to end of study
|
Number of participants achieving complete remission, partial remission, clinical improvement, progressive disease and stable disease. |
From start of treatment to end of study
|
|
Number of participants who have ≥ 25% spleen volume reduction
Lasso di tempo: Every 12 weeks from cycle 1 day 1 through cycle 19 day 1, and then every 24 weeks therafter during treatment.
|
Number of participants who have ≥ 25% spleen volume reduction compared to baseline |
Every 12 weeks from cycle 1 day 1 through cycle 19 day 1, and then every 24 weeks therafter during treatment.
|
|
Number of participants with ≥ 50% improvement in total symptom score (TSS50) at week 24
Lasso di tempo: 24 weeks
|
Number of participants who have ≥ 50% total symptom score reduction by MFSAF compared to baseline after 24 weeks of treatment. |
24 weeks
|
|
Determine the change in Patient Global Impression of Change (PGIC) at week 24 through end of study.
Lasso di tempo: After 24 weeks of treatment to end of study
|
Change in PGIC score |
After 24 weeks of treatment to end of study
|
|
Determine the incidence of QT interval changes
Lasso di tempo: 25 hours
|
Changes in QT interval and heart rhythm |
25 hours
|
|
Establish the half-life (t½) of nuvisertib monotherapy, in combination with ruxolitinib, and in combination with momelotinib
Lasso di tempo: 24 hours
|
The estimate of time for the nuvisertib concentration or amount to be reduced by half |
24 hours
|
|
Establish the Area under the plasma concentration versus time curve (AUC) of nuvisertib monotherapy, in combination with ruxolitinib, and in combination with momelotinib
Lasso di tempo: 24 hours
|
The amount of drug exposure over 24 hours period after administration |
24 hours
|
|
Establish the Peak Plasma Concentration (Cmax) of nuvisertib monotherapy, in combination with ruxolitinib, and in combination with momelotinib
Lasso di tempo: 24 hours
|
The maximum nuvisertib concentration after administration |
24 hours
|
|
Establish the Time of Maximum concentration observed (tmax) of nuvisertib monotherapy, in combination with ruxolitinib, and in combination with momelotinib
Lasso di tempo: 24 hours
|
The time to reach maximum nuvisertib concentration |
24 hours
|
Altre misure di risultato
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Numero di pazienti con riduzione della fibrosi del midollo osseo
Lasso di tempo: Ogni 24 settimane fino alla fine dello studio
|
Ogni 24 settimane fino alla fine dello studio
|
|
|
Bracci di associazione con nuvisertib: valutare l’aumento dell’emoglobina ≥ 1,5 o ≥ 2 g/dl rispetto al basale
Lasso di tempo: Dall'inizio del trattamento alla fine dello studio
|
Dall'inizio del trattamento alla fine dello studio
|
|
|
Bracci di combinazione con Nuvisertib: valutare lo stato di indipendenza dalle trasfusioni di globuli rossi o qualsiasi modifica dei requisiti
Lasso di tempo: Dall'inizio del trattamento alla fine dello studio
|
Dall'inizio del trattamento alla fine dello studio
|
|
|
Nuvisertib Monoterapia: cambiamenti nella conta piastrinica nel tempo nei pazienti con conta piastrinica basale <100 x 10^9/L
Lasso di tempo: Dall'inizio del trattamento alla fine dello studio
|
Dall'inizio del trattamento alla fine dello studio
|
|
|
Study potential pharmacodynamic (PD) markers of nuvisertib
Lasso di tempo: 12 months
|
Evaluate exploratory biomarkers, including change in protein phosphorylation and inflammatory cytokines, in peripheral blood samples and bone marrow biopsy samples. |
12 months
|
|
Establish overall survival
Lasso di tempo: From start of treatment to end of study
|
The time interval from treatment start date to date of death from any cause |
From start of treatment to end of study
|
Collaboratori e investigatori
Sponsor
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- BBI-TP-3654-102
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .